Two depression treatments can sound equally promising in a doctor's office and turn out to be completely different experiences once your insurance gets involved. One comes with a well-worn approval path. The other comes with a price sheet and a shrug. The difference usually traces back to one thing: how the FDA classifies the treatment for your condition.

This comparison looks at five options through the lens that matters most to people with commercial insurance: the paperwork trail. It is not a ranking of effectiveness, and it is not medical advice.

Why regulatory status is on the table at all

Our commissioned poll gathered 443 adults living in ten Midwest states. FDA approval would weigh heavily on trying a new depression treatment for 59 percent of them, whether as the deciding factor or a big one. Picking two provider priorities, respondents put FDA-approved treatment in their top two at 27 percent and fast results at 24 percent. Every figure is final, drawn from Pollfish's validated panel.

Insurance dwarfed both. Coverage landed in the top two for 85 percent. For the 173 respondents with commercial insurance, it was 84 percent. For commercially insured patients, those priorities are linked, because FDA status often shapes what your plan will do.

Option 1: A new oral antidepressant

FDA status: Approved for depression, in most cases.
Billing channel: Pharmacy benefit.
Typical paperwork: Often none for generics. Brand-name drugs may require prior authorization or step therapy, meaning cheaper drugs first.
Who files: Your prescriber, if anyone.
Time to start: Usually days.

The lightest paperwork of any option. It is also the path many people have already walked more than once.

Option 2: Esketamine (Spravato)

FDA status: Approved for treatment-resistant depression, under a restricted safety program. Doses happen only at certified sites, and patients stay two hours or more to be watched.
Billing channel: Varies by plan. Sometimes medical benefit, sometimes specialty pharmacy, with the monitored visit billed separately.
Typical paperwork: Prior authorization is standard. Expect to document the diagnosis and the antidepressants already tried.
Who files: Usually the treating clinic, sometimes with records from your prescriber.
Time to start: Often a couple of weeks, depending on how complete your records are.

Approval gives this option a defined path, and the manufacturer offers a savings program for eligible commercially insured patients. The tradeoff is logistics: no driving until the next day and a full night's rest, and in the early weeks visits usually come twice weekly. Brain Recovery Centers walks through the Spravato visit and its paperwork.

Option 3: TMS (transcranial magnetic stimulation)

FDA status: Cleared as a device for adults whose depression antidepressants have not eased.
Billing channel: Medical benefit.
Typical paperwork: Prior authorization, usually requiring several documented antidepressant trials and sometimes a trial of psychotherapy.
Who files: The TMS provider, using your records.
Time to start: Often one to a few weeks.

Cleared is the normal status for devices, not a lesser one. TMS involves no medication, and most people drive themselves. The course is demanding, often five sessions a week for four to six weeks, and coinsurance applies to every session.

Option 4: IV ketamine

FDA status: Ketamine is approved as an anesthetic. Use for depression is off-label.
Billing channel: Frequently none. Many clinics operate on a self-pay basis.
Typical paperwork: If you seek reimbursement, you may submit claims yourself, and denials are common. Some plans may cover portions of the visit.
Who files: Often you.
Time to start: Can be fast, because there is no authorization to wait on.

Speed and simplicity are real advantages here, but they come with less regulatory review for this use and the likelihood that the full cost is yours.

Option 5: At-home ketamine

FDA status: Not FDA-approved for depression. Many products are compounded, and the FDA has issued warnings about compounded ketamine used with nobody monitoring.
Billing channel: Generally self-pay, often through subscription pricing.
Typical paperwork: An online evaluation, usually no insurance involvement.
Who files: No one, in most cases.
Time to start: Can be very fast.

This is the simplest paperwork trail and the least regulated option on the list. It is a different category from supervised esketamine, and treating them as interchangeable is a mistake.

The pattern

Read top to bottom, a pattern shows up. The more regulatory review a treatment has for depression, the more paperwork your commercial plan tends to ask for, and the more likely it is to help pay. The less review, the less paperwork, and the more likely the bill lands on you.

People in our survey seemed to accept that trade. Given a choice between an insured option with more hoops and a pay-yourself option that was simpler, 51 percent chose the hoops. Paying their own way appealed to 23 percent; 26 percent were torn.

Making the paperwork easier

Build your medication history now. Drug names, doses, dates, and what happened. It is the core of nearly every prior authorization.
Ask your plan for the written policy on the specific treatment, not just your benefits summary.
Confirm the billing channel so you know which deductible and cost sharing apply.
Keep a call log with dates, names, and reference numbers.
Know your appeal rights. Internal appeal first, then often an independent external review.

Where to begin

With your doctor. A doctor's word carried the most weight in our poll: for 74 percent of respondents, their own physician recommending a new treatment would be what tips them into trying it. Your doctor can tell you which of these five options fits your history, which is also the question that determines how much paperwork follows.

No option here is certain to help, and whether one suits you is for a clinician who knows you to decide.

If you are thinking about suicide, set the paperwork aside. Dial or text 988 any hour; the Suicide and Crisis Lifeline needs no forms, no referral, and no plan ID.

Methodology

This article's numbers come from one Pollfish consumer panel survey. Completed by 443 adults, every one aged 18 to 64, in Oklahoma, Illinois, Nebraska, Kansas, Minnesota, Missouri, Iowa, Wisconsin, Indiana, and Ohio, it closed June 23, 2026. Results are final now that the panel's validation is done; one figure covers the commercial insurance group alone. We, the publisher, commissioned the research and paid its full cost.

The paperwork behind each depression option on a commercial plan